FDA extends abortion pill safety review into 2025
Source Summary
The FDA announced that its safety review of the nation's primary abortion pill will extend into next year. The extended timeline has drawn swift criticism from abortion rights opponents who seek to restrict the drug's availability.
Why it matters
The FDA's extended review timeline directly affects the regulatory status and potential availability of a widely used medication in ongoing U.S. abortion policy debates.
What remains uncertain
The source does not specify the exact completion date of the safety review or what specific findings or determinations may result from it.
